Results for tropicalis translation from Slovak to English

candida tropicalis
candida tropicalis

pazúrnatky (xenopus laevis a xenopus tropicalis)
xenopus (xenopus laevis and xenopus tropicalis)

Žaba [xenopus (laevis, tropicalis), rana (temporaria, pipiens)]
frog (xenopus (laevis, tropicalis), rana (temporaria, pipiens))

druhy najčastejšie zapríčiňujúce infekcie u ľudí zahŕňajú c. albicans, c. parapsilosis, c. tropicalis,
the species most frequently involved in causing human infections include c. albicans, c. parapsilosis,

1mic sú pre c. tropicalis o 1-2 stupne dvojnásobného riedenia vyššie ako pre c.albicans a c.glabrata.
1 mics for c. tropicalis are 1-2 two-fold dilution steps higher than for c albicans and c. glabrata.

Účinok in vitro anidulafungín vykazoval účinok in vitro na c. albicans, c. glabrata, c parapsilosis a c. tropicalis.
activity in vitro anidulafungin exhibited in-vitro activity against c. albicans, c. glabrata, c. parapsilosis, and c. tropicalis.

3 v klinických štúdiách bola odpoveď na vorikonazol u infekcií c. krusei podobná ako u c. albicans, c. parapsilosis a c. tropicalis.
3 in clinical studies, response to voriconazole in c. krusei infections was similar to c. albicans, c. parapsilosis and c. tropicalis.

3 v klinických štúdiách bola odpoveď na vorikonazol u infekcií spôsobených c. krusei podobná ako u c. albicans, c. parapsilosis a c. tropicalis.
3 in clinical studies, response to voriconazole in c. krusei infections was similar to c. albicans, c. parapsilosis and c. tropicalis.

anidulafungín preukázal in-vitro účinok na c. albicans, c. glabrata, c. parapsilosis, c. krusei a c. tropicalis.
anidulafungin exhibited in-vitro activity against c. albicans, c. glabrata, c. parapsilosis, c. krusei and c. tropicalis.

Úspešný výsledok bol v klinických štúdiách numericky mierne nižší pre c. tropicalis než pre c. albicans, čo platí pre obe dávky (100 a 150 mg na deň).
in the clinical study, successful outcome was numerically slightly lower for c. tropicalis than for c. albicans at both dosages (100 and 150 mg daily).

2 v klinických štúdiách bola odpoveď na vorikonazol u pacientov s infekciami spôsobenými c. glabrata o 21 % nižšia v porovnaní s c. albicans, c. parapsilosis a c. tropicalis.
2 in clinical studies, response to voriconazole in patients with c. glabrata infections was 21% lower compared to c. albicans, c. parapsilosis and c. tropicalis.

9 mikrobiológia ukázalo sa, že posakonazol je in vitro účinný proti nasledujúcim mikroorganizmom: druhy aspergillus (aspergillus fumigatus, a. flavus, a. terreus, a. nidulans, a. niger, a. ustus), druhy candida (candida albicans, c. glabrata, c. krusei, c. parapsilosis, c. tropicalis, c. dubliniensis, c. famata, c. incospicua, c. lipolytica, c. norvegensis, c. pseudotropicalis), coccidioides immitis, fonsecaea pedrosoi a druhy fusarium, rhizomucor, mucor a rhizopus.
aspergillus species (aspergillus fumigatus, a. flavus, a. terreus, a. nidulans, a. niger, a. ustus), candida species (candida albicans, c. glabrata, c. krusei, c. parapsilosis, c. tropicalis, c. dubliniensis, c. famata, c. inconspicua, c. lipolytica, c. norvegensis, c. pseudotropicalis), coccidioides immitis, fonsecaea pedrosoi, and species of fusarium, rhizomucor, mucor, and rhizopus.